Dominic Richmond | Health Professions | Best Researcher Award

Published on by Innovation Technologist

Best Researcher Award

Dominic Richmond
University of Birmingham, United Kingdom
Dominic Richmond
Affiliation University of Birmingham
Country United Kingdom
Scopus ID 57189870953
Documents 2
Citations 32
h-index 2
Subject Area Health Professions
Event Global Innovation Technologist Awards
ORCID 0009-0001-9270-937X

Dominic Richmond is a United Kingdom-based physiotherapy researcher and advanced clinical practitioner associated with the University of Birmingham and Cambridge University Hospitals NHS Foundation Trust. His academic and clinical work focuses on musculoskeletal rehabilitation, anterior cruciate ligament (ACL) injury management, sports physiotherapy, and evidence-based rehabilitation practices. Richmond has contributed to clinical research addressing return-to-sport outcomes and musculoskeletal injury prevention within elite athletic and healthcare environments.[1] His profile reflects a combination of academic achievement, clinical leadership, and interdisciplinary healthcare research aligned with contemporary health professions scholarship.[2]

Abstract

This article presents an academic overview of Dominic Richmond, a physiotherapist and healthcare researcher whose work has contributed to sports medicine, musculoskeletal rehabilitation, and anterior cruciate ligament research. Richmond’s clinical and academic activities integrate evidence-based rehabilitation methods with applied healthcare delivery in hospital and elite sporting environments. His published work and conference contributions demonstrate continuing engagement with ACL rehabilitation pathways, return-to-sport assessment methodologies, and injury risk mitigation strategies.[3] The profile also highlights his participation in healthcare leadership, interdisciplinary clinical practice, and research-oriented physiotherapy education.[4]

Keywords

Health Professions, Physiotherapy, ACL Rehabilitation, Sports Medicine, Musculoskeletal Research, Evidence-Based Practice, Clinical Rehabilitation, Knee Injury Research, Return-to-Sport Testing, Advanced Physiotherapy Practice

Introduction

Contemporary healthcare systems increasingly emphasize interdisciplinary rehabilitation, injury prevention, and evidence-informed physiotherapy interventions. Within this context, clinicians engaged in both practical and academic healthcare activities contribute significantly to the development of patient-centered rehabilitation frameworks. Dominic Richmond’s professional profile illustrates the integration of advanced physiotherapy practice with sports medicine research and musculoskeletal healthcare delivery.[5]

Richmond has worked across clinical, academic, and elite sports environments, including orthopaedic clinics, rehabilitation programs, and research-focused healthcare initiatives. His involvement with Cambridge University Hospitals NHS Foundation Trust and postgraduate studies at the University of Birmingham reflects continued engagement with advanced clinical reasoning, healthcare education, and translational rehabilitation research.[2]

Research Profile

Dominic Richmond’s research profile centers on physiotherapy, sports rehabilitation, and musculoskeletal injury management. His Scopus author profile records publications and citations related to ACL rehabilitation and return-to-sport methodologies.[1] His research interests include knee rehabilitation, strength and conditioning, injury prevention, and evidence-based physiotherapy interventions.

In addition to peer-reviewed publications, Richmond has participated in scientific conferences including the European College of Sport Science and UK Strength and Conditioning Association meetings. These activities demonstrate engagement with international scientific communication and collaborative research dissemination.[6]

  • Advanced Practice Physiotherapist specializing in knee rehabilitation and ACL pathways
  • Research involvement in sports medicine and return-to-sport evaluation
  • Participation in NIHR Health and Care Professional Internship Programme
  • Contributor to musculoskeletal physiotherapy education and clinical supervision

Research Contributions

Richmond has contributed to research examining injury rehabilitation strategies and musculoskeletal performance outcomes. His published and presented work includes investigations into ACL rehabilitation pathways and muscle-tendon mechanics associated with eccentric training interventions.[7]

His research collaborations have explored risk factors associated with sports-related injuries and return-to-sport testing after ACL reconstruction. These studies contribute to ongoing discussions concerning rehabilitation quality, athlete recovery, and evidence-based physiotherapy practice.[8]

  • Research on ACL injury priorities among at-risk female populations
  • Systematic review and meta-analysis related to return-to-sport testing
  • Conference presentations involving muscle-tendon mechanics and eccentric training
  • Clinical audit and healthcare improvement initiatives in musculoskeletal services

Publications

  1. Richmond, D., White, C., & Gomulko, T. Pass Rates of Return to Sport Test Batteries Following Anterior Cruciate Ligament Reconstruction: A Systematic Review and Meta-Analysis. Sports, 2026.
  2. Kay, A.D., Richmond, D., Talbot, C., Mina, M., Baross, A.W., & Blazevich, A.J. Stretching of Active Muscle Elicits Chronic Changes in Multiple Strain Risk Factors. Medicine & Science in Sports & Exercise, 2016.
  3. Research priorities for ACL injuries in at-risk groups – The female population. Published in Knee, 2025.[1]

Research Impact

Richmond’s academic output demonstrates measurable engagement within sports medicine and physiotherapy literature. According to Scopus metrics, his publications have received scholarly citations that reflect emerging influence within musculoskeletal rehabilitation research.[1] His work addressing ACL rehabilitation contributes to contemporary discussions concerning rehabilitation benchmarks, athlete recovery standards, and evidence-informed return-to-sport assessments.

Beyond publication metrics, Richmond’s research impact is reinforced by his participation in healthcare leadership programs, conference presentations, and integration of research findings into clinical rehabilitation pathways. Such contributions support broader healthcare objectives focused on patient outcomes, rehabilitation quality, and multidisciplinary collaboration.[4]

Award Suitability

Dominic Richmond’s professional and academic profile aligns with the objectives commonly associated with the Best Researcher Award within the Global Innovation Technologist Awards framework. His combined contributions to clinical physiotherapy, musculoskeletal rehabilitation research, healthcare education, and interdisciplinary sports medicine demonstrate engagement with both scientific inquiry and applied healthcare innovation.[9]

The integration of evidence-based rehabilitation methods into advanced clinical practice, alongside conference participation and peer-reviewed publications, reflects sustained commitment to healthcare advancement. His role in ACL rehabilitation leadership and musculoskeletal clinical services further supports recognition within professional health professions awards programs.[5]

Conclusion

Dominic Richmond represents an emerging contributor within physiotherapy and sports rehabilitation research. His academic publications, clinical leadership activities, and participation in healthcare-focused research initiatives collectively demonstrate ongoing engagement with musculoskeletal rehabilitation science and evidence-based healthcare practice. Through collaborative research, advanced clinical service delivery, and scholarly dissemination, Richmond contributes to the evolving landscape of health professions and rehabilitation medicine.[3]

References

  1. Elsevier. (n.d.). Scopus author details: Dominic Richmond, Author ID 57189870953. Scopus.
    www.scopus.com/authid/detail.uri?authorId=57189870953
  2. University of Birmingham. (2025). Academic and professional profile associated with advanced physiotherapy studies and healthcare practice.
  3. ORCID. (2026). Dominic Richmond ORCID Profile.
    orcid.org/0009-0001-9270-937X
  4. Cambridge University Hospitals NHS Foundation Trust. (2026). Advanced Practice Physiotherapy and rehabilitation leadership activities.
  5. Richmond, D. (2026). Clinical rehabilitation and ACL management contributions in musculoskeletal healthcare.
  6. European College of Sport Science. (2013). Conference proceedings and research presentation abstracts involving muscle-tendon mechanics.
  7. Kay, A.D., Richmond, D., Talbot, C., Mina, M., Baross, A.W., & Blazevich, A.J. (2016). Stretching of Active Muscle Elicits Chronic Changes in Multiple Strain Risk Factors. Medicine & Science in Sports & Exercise.
  8. Richmond, D., White, C., & Gomulko, T. (2026). Pass Rates of Return to Sport Test Batteries Following Anterior Cruciate Ligament Reconstruction: A Systematic Review and Meta-Analysis. Sports.
    doi.org/10.3390/sports14050211
  9. Global Innovation Technologist Awards. (2026). International recognition framework for innovation and research excellence.
    innovationtechnologist.com

Mutinda Cleophas Kyama | Medicine and Health Sciences | Research Excellence Award

Published on by Innovation Technologist

Research Excellence Award

Cleophas Mutinda Kyama
Jomo Kenyatta University of Agriculture and Technology, Kenya
Cleophas Mutinda Kyama
Affiliation Jomo Kenyatta University of Agriculture and Technology
Country Kenya
Scopus ID 57216717397
Documents 65
Citations 2,698
h-index 29
Subject Area Medicine and Health Sciences
Event Global Innovation Technologist Awards
ORCID 0000-0001-6459-1514

Cleophas Mutinda Kyama is a Kenyan biomedical scientist, clinical cytologist, and academic researcher associated with the Jomo Kenyatta University of Agriculture and Technology (JKUAT). His scholarly contributions span cancer biology, molecular diagnostics, parasitology, toxicology, infectious disease detection, and translational biomedical sciences. His publication record demonstrates sustained engagement in interdisciplinary health science research with applications in oncology, infectious diseases, immunology, and molecular medicine.[1] The researcher has received significant scholarly attention through citations and collaborative biomedical investigations, particularly in cervical cancer diagnostics, phytomedicine, CRISPR-based diagnostic technologies, and antivenom development.[2]

Abstract

The Research Excellence Award recognition article documents the scholarly achievements and biomedical research contributions of Cleophas Mutinda Kyama. His scientific portfolio encompasses molecular diagnostics, oncology, pharmacological investigations, parasitology, immunological research, and translational health sciences. Through peer-reviewed publications, collaborative international research, and laboratory-based innovations, Kyama has contributed to the advancement of diagnostic technologies and therapeutic investigations relevant to public health challenges in Africa and globally.[3] The researcher’s work demonstrates integration of computational biology, molecular docking, in vitro experimentation, and nanotechnology-assisted diagnostics, reflecting contemporary interdisciplinary scientific approaches.[4]

Keywords

Biomedical Sciences; Molecular Diagnostics; Cervical Cancer Research; CRISPR-Cas12a; Oncology; Cytology; Antivenom Research; Pharmacology; Translational Medicine; Public Health Research; Cancer Therapeutics; Computational Biology.

Introduction

Biomedical and translational health sciences have increasingly relied upon interdisciplinary approaches integrating molecular biology, computational modeling, immunology, and experimental medicine. Within this scientific landscape, Cleophas Mutinda Kyama has contributed to research efforts addressing infectious diseases, cancer diagnostics, toxicology, and therapeutic screening technologies.[5] His work has emphasized practical healthcare applications, particularly within African biomedical contexts where diagnostic accessibility and disease management remain major public health priorities.

Kyama’s research trajectory demonstrates sustained engagement in clinically relevant investigations involving HPV-associated cervical cancer screening, SARS-CoV-2 detection systems, phytochemical anticancer studies, and venom toxicology. Several of his investigations combine computational methodologies with laboratory validation, contributing to evidence-based biomedical innovation and translational healthcare research.[6]

Research Profile

Cleophas Mutinda Kyama served at Jomo Kenyatta University of Agriculture and Technology as a Biomedical Scientist and Senior Lecturer in Medical Laboratory Sciences. His academic and professional work has focused on laboratory diagnostics, cytology, cancer biology, molecular therapeutics, and pathogen detection technologies.[1]

The researcher’s Scopus profile reports 65 scholarly documents with 2,698 citations and an h-index of 29, reflecting measurable scientific visibility and sustained citation impact across biomedical disciplines.[1] His work has appeared in journals including PLOS ONE, BMC Complementary Medicine and Therapies, Diagnostics, Toxicon: X, Toxins, and the South African Journal of Botany.

  • Research specialization in molecular diagnostics and biomedical laboratory sciences.
  • Interdisciplinary research combining computational biology and experimental medicine.
  • Published investigations involving oncology, toxicology, parasitology, and virology.
  • Contributions to public health-oriented biomedical innovation.

Research Contributions

Among Kyama’s notable scientific contributions are investigations into cervical cancer therapeutics and molecular screening technologies. His 2025 study in PLOS ONE explored the molecular mechanisms of Solanecio mannii aqueous root extracts against cervical cancer using computational and experimental validation methodologies.[2]

Additional research explored network pharmacology and molecular docking strategies for prostate cancer treatment investigations using Aspilia pluriseta. These studies integrated in vitro analysis with computational biology techniques to evaluate antiproliferative activity and potential therapeutic mechanisms.[3]

Kyama also contributed to advanced infectious disease diagnostics through CRISPR-Cas12a and hybridization chain reaction methodologies for SARS-CoV-2 detection. This work reflected the growing importance of rapid molecular diagnostic systems during global public health emergencies.[4]

In toxicological and immunological sciences, his studies investigated venom lethality, monoclonal antibody development, and antivenom efficacy involving Naja ashei toxins. These investigations contributed to understanding envenomation management and toxin-neutralizing biomedical strategies.[7]

Publications

Selected publications associated with Cleophas Mutinda Kyama include peer-reviewed journal articles, preprints, and translational biomedical studies relevant to oncology, diagnostics, toxicology, and parasitology.

  1. Computational investigation and experimental validation of the molecular mechanism of Solanecio mannii aqueous roots extract against cervical cancer. PLOS ONE (2025).
  2. Network pharmacology, molecular docking, and in vitro study on Aspilia pluriseta against prostate cancer. BMC Complementary Medicine and Therapies (2024).
  3. Application of Hybridization Chain Reaction/CRISPR-Cas12a for the Detection of SARS-CoV-2 Infection. Diagnostics (2023).
  4. Evaluation of lethality and cytotoxic effects induced by Naja ashei venom and efficacy of selected antivenoms in Kenya. Toxicon: X (2022).
  5. Development and Characterization of Anti-Naja ashei Three-Finger Toxins-Specific Monoclonal Antibodies. Toxins (2022).

Research Impact

The scientific impact of Cleophas Mutinda Kyama’s work is reflected through citation metrics, interdisciplinary collaborations, and practical biomedical applications. His investigations into molecular diagnostics and therapeutic evaluation contribute to contemporary discussions surrounding affordable healthcare technologies, precision diagnostics, and evidence-based medicinal research.[4]

Research involving CRISPR-based diagnostics and nanoparticle-assisted detection systems demonstrates alignment with emerging biomedical technologies that support rapid pathogen identification and translational healthcare innovation.[8] Similarly, his toxicological and antivenom studies address healthcare concerns related to snakebite management in endemic regions.

The integration of phytomedicine, computational molecular analysis, and laboratory validation techniques further reflects a multidisciplinary scientific framework capable of supporting future biomedical innovation and collaborative translational research initiatives.[3]

Award Suitability

The scholarly profile of Cleophas Mutinda Kyama demonstrates characteristics associated with international academic recognition and research excellence awards. His documented publication history, citation impact, interdisciplinary biomedical investigations, and sustained engagement in translational health sciences collectively support recognition within the framework of the Global Innovation Technologist Awards.[1]

  • Demonstrated publication productivity in indexed scientific journals.
  • Strong citation impact and measurable academic influence.
  • Contributions to molecular diagnostics and translational medicine.
  • Interdisciplinary biomedical innovation relevant to public health.
  • Research engagement involving computational and experimental methodologies.

Conclusion

Cleophas Mutinda Kyama has established a research profile characterized by interdisciplinary biomedical inquiry, molecular diagnostic innovation, and translational scientific investigations addressing major health challenges. His academic contributions in oncology, toxicology, molecular biology, and infectious disease diagnostics demonstrate sustained scholarly engagement and measurable scientific impact.[5] Through collaborative biomedical research and publication activity, his work contributes to evolving scientific understanding within medicine and health sciences while supporting broader healthcare research objectives relevant to emerging global health priorities.

References

  1. Elsevier. (n.d.). Scopus author details: Cleophas Mutinda Kyama, Author ID 57216717397. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57216717397
  2. Kyama, C. M. et al. (2025). Computational investigation and experimental validation of the molecular mechanism of Solanecio mannii aqueous roots extract against cervical cancer. PLOS ONE.
    https://doi.org/10.1371/journal.pone.0323680
  3. Kyama, C. M. et al. (2024). Network pharmacology, molecular docking, and in vitro study on Aspilia pluriseta against prostate cancer. BMC Complementary Medicine and Therapies.
    https://doi.org/10.1186/s12906-024-04642-8
  4. Kyama, C. M. et al. (2023). Application of Hybridization Chain Reaction/CRISPR-Cas12a for the Detection of SARS-CoV-2 Infection. Diagnostics.
    https://doi.org/10.3390/diagnostics13091644
  5. Jomo Kenyatta University of Agriculture and Technology. (n.d.). Medical Laboratory Sciences and Biomedical Research Activities.
  6. Kyama, C. M. et al. (2022). Expression of the Fab enzymes from Plasmodium falciparum after exposure to Artemisia afra plant extracts. Journal of Parasitic Diseases.
    https://doi.org/10.1007/s12639-022-01537-8
  7. Kyama, C. M. et al. (2022). Development and Characterization of Anti-Naja ashei Three-Finger Toxins-Specific Monoclonal Antibodies. Toxins.
    https://doi.org/10.3390/toxins14040285
  8. Kyama, C. M. et al. (2020). Development of HPV 16/18 E6 oncoprotein paper-based nanokit for enhanced cervical cancer screening.
    https://doi.org/10.1101/2020.04.29.20084459

Ankana Daga | Medicine and Health Sciences | Innovative Research Award

Published on by Innovation Technologist

Innovative Research Award

Ankana Daga
Boston Children’s Hospital, Harvard Medical School
Ankana Daga
Affiliation Boston Children’s Hospital
Country United States
Scopus ID 55893187400
Documents 35
Citations 1,820
h-index 21
Subject Area Medicine and Health Sciences
Event Global Innovation Technologist Awards
Google Scholar ID TVK8miwAAAAJ

Ankana Daga is a researcher affiliated with Boston Children’s Hospital and Harvard Medical School whose scholarly work has contributed significantly to the fields of nephrology, genomics, precision medicine, and rare kidney disease research. Her academic publications demonstrate consistent engagement with whole-exome sequencing methodologies, monogenic kidney disorders, and translational biomedical science. The research profile associated with her scholarly record reflects a sustained contribution to clinical genetics and pediatric nephrology research through collaborative and multidisciplinary investigation.[1]

Abstract

This academic recognition article presents an overview of the scientific contributions and research profile of Ankana Daga within the fields of medical genetics, nephrology, and precision medicine. The profile is characterized by high-impact publications related to whole-exome sequencing, congenital kidney disorders, nephrotic syndrome, and molecular diagnostics. The research demonstrates a strong emphasis on genomic methodologies and translational applications in clinical medicine. With an established citation record and an h-index indicative of sustained scholarly influence, the researcher’s contributions align with the objectives of the Global Innovation Technologist Awards in recognizing scientific advancement and innovation in healthcare research.[2]

Keywords

  • Precision medicine
  • Whole-exome sequencing
  • Nephrology
  • Clinical genomics
  • Rare kidney disease

Introduction

Contemporary biomedical research increasingly relies on genomic technologies to improve diagnostic precision and therapeutic decision-making. Within this evolving landscape, researchers working at the intersection of nephrology and molecular genetics have contributed substantially to the understanding of hereditary kidney disorders. Ankana Daga’s research portfolio reflects engagement with this interdisciplinary framework through publications focusing on monogenic diseases, nephrotic syndromes, and congenital anomalies affecting renal development.[3]

The researcher’s scholarly contributions have frequently involved collaborative investigations published in internationally recognized journals, including Nature Genetics, Kidney International, and the Journal of the American Society of Nephrology. These publications demonstrate the practical application of genomic sequencing technologies to pediatric and adult nephrology research while also supporting the broader advancement of precision medicine approaches in healthcare.[4]

Research Profile

According to the available academic metrics, Ankana Daga has authored or co-authored 35 indexed scholarly documents and accumulated approximately 1,820 citations, with an h-index of 21. These metrics indicate sustained engagement with high-impact biomedical research and a measurable influence within the scientific community.[1]

The research profile is strongly associated with studies involving genomic diagnostics and kidney disease genetics. Many of the publications focus on the implementation of whole-exome sequencing in identifying causative mutations responsible for nephrotic syndrome, nephrolithiasis, nephrocalcinosis, and congenital anomalies of the kidney and urinary tract. The interdisciplinary nature of the research further highlights integration between molecular biology, clinical nephrology, and translational medicine.[5]

Research Contributions

One of the notable contributions associated with the researcher includes investigations into steroid-resistant nephrotic syndrome using whole-exome sequencing methodologies. Such studies have improved understanding of genetic variants associated with complex kidney disorders and facilitated more accurate clinical characterization of affected patients.[6]

Additional research contributions involve the identification of mutations in KEOPS-complex genes and nuclear pore complex components linked to nephrotic syndrome and microcephaly. These findings contributed to expanding the understanding of molecular pathways involved in renal disease pathogenesis and rare developmental disorders.[7]

The researcher has also participated in studies demonstrating the utility of whole-exome sequencing in precision medicine approaches for kidney transplant recipients. This work highlights the clinical importance of genomic diagnostics in informing treatment decisions and improving patient-specific therapeutic strategies.[8]

  • Application of genomic sequencing in nephrology research
  • Investigation of hereditary kidney diseases
  • Development of precision medicine strategies
  • Clinical translational research in pediatric nephrology
  • Collaborative interdisciplinary biomedical research

Publications

  1. Whole exome sequencing of patients with steroid-resistant nephrotic syndrome. Clinical Journal of the American Society of Nephrology, 2018.
  2. Mutations in KEOPS-complex genes cause nephrotic syndrome with primary microcephaly. Nature Genetics, 2017.
  3. Whole-exome sequencing identifies causative mutations in families with congenital anomalies of the kidney and urinary tract. Journal of the American Society of Nephrology, 2018.
  4. Whole exome sequencing frequently detects a monogenic cause in early onset nephrolithiasis and nephrocalcinosis. Kidney International, 2018.
  5. Whole-exome sequencing enables a precision medicine approach for kidney transplant recipients. Journal of the American Society of Nephrology, 2019.

Research Impact

The research impact associated with Ankana Daga is reflected through both citation metrics and the clinical relevance of the published work. Publications linked to genomic sequencing and nephrology have contributed to advancements in disease diagnosis, clinical classification, and precision treatment strategies. Citation activity exceeding 1,800 citations indicates broad scholarly engagement with the research findings across multiple biomedical disciplines.[1]

Several publications have been recognized within high-impact journals, demonstrating the significance of the research within international scientific communities. The integration of genomic technologies into patient-centered nephrology research has further supported translational applications that bridge laboratory investigation with clinical practice.[4]

Award Suitability

The Global Innovation Technologist Awards recognize individuals whose work demonstrates innovation, scientific advancement, and measurable research impact. Based on the available academic indicators and publication record, Ankana Daga’s research profile aligns with several of these objectives through contributions to precision medicine, genomic diagnostics, and translational nephrology research.[9]

The combination of interdisciplinary collaboration, publication quality, citation influence, and clinical relevance supports the suitability of the researcher for recognition within international scientific award frameworks. The researcher’s scholarly contributions continue to support advancements in medical genetics and kidney disease diagnostics within the broader biomedical research community.[5]

Conclusion

Ankana Daga’s academic profile demonstrates sustained contributions to the advancement of genomic medicine and nephrology research. Through collaborative investigations, high-impact publications, and translational clinical applications, the researcher has contributed to improving understanding of hereditary kidney disorders and precision medicine methodologies. The scholarly record, citation performance, and research relevance collectively position the researcher as a noteworthy contributor within contemporary biomedical science.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Ankana Daga, Author ID 55893187400. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=55893187400
  2. Google Scholar. (n.d.). Academic citation profile of Ankana Daga.
    https://scholar.google.com/citations?user=TVK8miwAAAAJ
  3. Warejko JK, Tan W, Daga A, et al. (2018). Whole exome sequencing of patients with steroid-resistant nephrotic syndrome. Clinical Journal of the American Society of Nephrology.
    https://doi.org/10.2215/CJN.04120417
  4. Braun DA, Rao J, Mollet G, Daga A, et al. (2017). Mutations in KEOPS-complex genes cause nephrotic syndrome with primary microcephaly. Nature Genetics.
    https://doi.org/10.1038/ng.3933
  5. Van Der Ven AT, Connaughton DM, Ityel H, Daga A, et al. (2018). Whole-exome sequencing identifies causative mutations in families with congenital anomalies of the kidney and urinary tract. Journal of the American Society of Nephrology.
    https://doi.org/10.1681/ASN.2017121265
  6. Daga A, Majmundar AJ, Braun DA, et al. (2018). Whole exome sequencing frequently detects a monogenic cause in early onset nephrolithiasis and nephrocalcinosis. Kidney International.
    https://www.sciencedirect.com/science/article/pii/S0085253817304945
  7. Braun DA, Lovric S, Daga A, et al. (2018). Mutations in multiple components of the nuclear pore complex cause nephrotic syndrome. The Journal of Clinical Investigation.
    https://doi.org/10.1172/JCI98688
  8. Mann N, Braun DA, Daga A, et al. (2019). Whole-exome sequencing enables a precision medicine approach for kidney transplant recipients. Journal of the American Society of Nephrology.
    https://doi.org/10.1681/ASN.2018060575
  9. Global Innovation Technologist Awards. (n.d.). Official award platform and recognition program information.
    innovationtechnologist.com

Laura Moreno Galarraga | Health Professions | Excellence in Research Award

Published on by Innovation Technologist

Assoc. Prof. Dr. Laura Moreno Galarraga | Health Professions | Excellence in Research Award

Pediatrician at University Hospital of Navarre | Spain

Dr. Laura Moreno Galarraga is an accomplished pediatrician and academic specializing in pediatric pulmonology with extensive experience in both clinical practice and research. She earned her medical degree from the University of Navarra and completed her specialization in pediatrics at Virgen de las Nieves Hospital in Granada, followed by a Ph.D. in Medicine from the University of Granada. She has served as an Assistant Professor at the University of Navarra and later at the Public University of Navarra, contributing significantly to the fields of preventive medicine and child health. As a pediatric pulmonologist at the University Hospital of Navarra, she has developed expertise in respiratory disorders in children and has been accredited by the Spanish Association of Pediatrics. Dr. Moreno Galarraga leads the Preventive Pediatric Research Group at the Navarra Health Research Institute and coordinates the SENDO Pediatric Cohort Study. Her research focuses on preventive pediatrics, respiratory health, and the early determinants of childhood diseases. She has collaborated in multiple national and international clinical trials, including projects on influenza vaccination, respiratory infections, and vaccine immunogenicity. Her scholarly output includes numerous publications in peer-reviewed journals addressing pediatric asthma management, COVID-19, and cystic fibrosis. She is actively engaged in professional societies such as the Spanish Association of Pediatrics, the Spanish Society of Pediatric Pulmonology, and the European Respiratory Society, where she contributes to education and research initiatives on childhood respiratory health. Her dedication to pediatric research and medical education continues to influence preventive pediatric healthcare practices in Spain and beyond.

Profile: Orcid

Featured Publications

Moreno-Galarraga, L., Escrivá, N., Barado, E., Torres, M. G., & Fernandez-Montero, A. (2025). Association between acute COVID‐19 infection and long COVID in a non‐hospitalized population: A retrospective case‐control study. Health Science Reports, 8(8), e71043.

Erroz Ferrer, M., Paniagua García, M., Viguria Sánchez, N., & Moreno-Galarraga, L. (2025, August 20). The role of biologic therapy switching to optimize the treatment of severe pediatric asthma: Tezepelumab is a new therapeutic alternative for adolescents. Children, 12(8), 1092.

Moreno-Galarraga, L., García Vera, C., Rivero-Calle, I., Martinón-Torres, F., Díez López, I., Cabañas, F., & Calvo, C. (2025, July). Investigación pediátrica en España: desafíos y oportunidades. Anales de Pediatría, 103(7), 503854.

Garcia Gerriko, J., Simoneau, T., Gaffin, J. M., Ortúzar Menéndez, M., Fernandez-Montero, A., & Moreno-Galarraga, L. (2025, June). Impact of telemedicine on asthma control and quality of life in children and adolescents: A systematic review and meta-analysis. Children, 12(7), 849.

Chaverri Repáraz, C. M., Lacalle Fabo, E., Erroz Ferrer, M., Gimeno-Castillo, M., Castro-Garrido, I., Ibarzabal-Arregi, M., González Arza, N., Viguria, N., & Moreno-Galarraga, L. (2025, January). Tailoring biologic therapies for pediatric severe asthma: A comprehensive approach. Children, 12(2), 140.